Guaranteed Accomplishment with Newest Feb-2026 FREE SOCRA CCRP [Q46-Q68]

QUESTION 46
A subject on a multi-drug regimen could not tolerate a non-investigational drug. Can the investigational regimen continue?

QUESTION 47
A research protocol requires patients to complete a patient reported outcome questionnaire in the sponsor’s electronic data capture (EDC) system. What is the source data?

QUESTION 48
In accordance with ICH, which of the following is an acceptable protocol review frequency for an IRB?

QUESTION 49
According to the CFR and the ICH GCP Guideline, which of the following must be submitted to the IRB after completion of the trial at the site?

QUESTION 50
In accordance with the CFR, which of the following statements regarding the informed consent document is correct?

QUESTION 51
In accordance with the ICH GCP Guideline, at what intervals should the on-site study monitoring be performed?

QUESTION 52
A research protocol requires patients to complete a patient reported outcome questionnaire in the sponsor’s electronic data capture (EDC) system. What is the source data?

QUESTION 53
According to the ICH/GCP Guideline, which of the following should a sponsor provide to the clinical investigator before entering into a clinical trial agreement?

QUESTION 54
A study subject in a double-blinded, placebo-controlled Phase III study experienced a serious adverse event that could be related to the study drug. The clinical investigator is out of town, and the sub-investigator needs to break the blind. Where can the sub-investigator find a description of the unblinding procedure?

QUESTION 55
An investigator’s responsibilities for conducting clinical trials include:

QUESTION 56
The FDA may propose to terminate an IND during a Phase I study if the FDA finds that which of the following conditions exists?

QUESTION 57
According to 21 CFR Part 11, each electronic signature must be unique and:

QUESTION 58
A research assistant on a study was recently promoted to a clinical research coordinator (CRC) role after one year on the study. In order to fulfill the significant new responsibilities, the CRC completed additional institutional training. According to ICH GCP Guidelines and 21 CFR, which of the following must be filed in the regulatory binder?

QUESTION 59
For a study with a significant risk investigational medical device that could optimize the effects of radiation therapy on cancer tumors, the investigational plan states mild burns are an anticipated effect. One subject developed severe burns with blistering. In accordance with the CFR, this effect must be reported to the sponsor and the IRB/IEC as soon as possible and at most how long after the investigator first learns of the effect?

QUESTION 60
A clinical investigator is developing the assent procedure for the enrollment of children into a new pediatric clinical trial. The ages of the children are described in the IRB/IEC submission. A description of which of the following must also be included in the submission?

QUESTION 61
Before approving a research protocol, an IRB/IEC must determine compliance with which of the following requirements?

QUESTION 62
The sponsor of a multi-institutional clinical trial provided a site with information regarding a newly identified unanticipated adverse event attributed to study drug administration. The site’s investigator has a subject actively receiving this study drug. Which of the following is the site investigator’s responsibility to the subject?

QUESTION 63
An unconscious patient experiencing life-threatening cardiac arrhythmias has been admitted to an emergency room. No FDA-approved treatment is available, and no legal representative is present. The clinical investigator determined that the use of an investigational antiarrhythmic drug is required. In accordance with the CFR, who must certify the investigator’s determination?

QUESTION 64
Protocol increases drug dose by 20%. Baseline: 370 mg/m². New dose = ?

QUESTION 65
Which of the following statements about the investigator’s brochure is correct?

QUESTION 66
When can the IRB/IEC require that additional information be given to subjects as part of informed consent?

QUESTION 67
On 15 May 2019, a sponsor announced that its investigational compound GHB33IA will not be investigated any further and will not be pursued for a marketing approval. According to the CFR, what is the earliest date when the site may begin to destroy the study records?

QUESTION 68
Which of the following elements should NOT influence the investigator’s ability to obtain endpoint data?